Pulmonary Thrombosis or Embolism in a Large Cohort of Hospitalized Patients With Covid-19

Pulmonary Thrombosis or Embolism in a Large Cohort of Hospitalized Patients With Covid-19

Natividad Benito, Natividad Benito, Natividad Benito, David Filella, David Filella, Jose Mateo, Ana M. Fortuna, Juan E. Gutierrez-Alliende, Nerea Hernandez, Nerea Hernandez, Ana M. Gimenez, Virginia Pomar, Virginia Pomar, Virginia Pomar, Ivan Castellvi, Ivan Castellvi, Hector Corominas, Hector Corominas, Jordi Casademont, Jordi Casademont, Pere Domingo, Pere Domingo

Objective: We set out to analyze the incidence and predictive factors of pulmonary embolism (PE) in hospitalized patients with Covid-19.Methods: We prospectively collected data from all consecutive patients with laboratory-confirmed Covid-19 admitted to the Hospital de la Santa Creu i Sant Pau, a university hospital in Barcelona, between March 9 and April 15, 2020. Patients with suspected PE, according to standardized guidelines, underwent CT pulmonary angiography (CTPA).Results: A total of 1,275 patients with Covid-19 were admitted to hospital. CTPA was performed on 76 inpatients, and a diagnosis of PE was made in 32 (2.6% [95%CI 1.7–3.5%]). Patients with PE were older, and they exhibited lower PaO2:FiO2 ratios and higher levels of D-dimer and C-reactive protein (CRP). They more often required admission to ICU and mechanical ventilation, and they often had longer hospital stays, although in-hospital mortality was no greater than in patients without PE. High CRP and D-dimer levels at admission (≥150 mg/L and ≥1,000 ng/ml, respectively) and a peak D-dimer ≥6,000 ng/ml during hospital stay were independent factors associated with PE. Prophylactic low molecular weight heparin did not appear to prevent PE. Increased CRP levels correlated with increased D-dimer levels and both correlated with a lower PaO2:FiO2.Conclusions: The 2.6% incidence of PE in Covid-19 hospitalized patients is clearly high. Higher doses of thromboprophylaxis may be required to prevent PE, particularly in patients at increased risk, such as those with high levels of CRP and D-dimer at admission. These findings should be validated in future studies.

2020

covid-19, thromboprophylaxis, thromboinflammation, Pulmonary thrombosis, pulmonary embolism (MeSH), anticoagulant (MeSH)

10.3389/fmed.2020.00557

Epidemiology and Health

Korean Society of Epidemiology

Medicine (General)